KDR and neoplasm: An alternative approach for non-druggable mutations is targeting the tumor’s microenvironment with immunotherapy such as Programmed-Death-Ligand-1(PDL-1) Inhibitors in combination with a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.